TY - JOUR
T1 - Deferasirox Derivatives
T2 - Ligands for the Lanthanide Series
AU - Mangel, Daniel n.
AU - Juarez, Gabriel j.
AU - Carpenter, Stephanie h.
AU - Steinbrueck, Axel
AU - Lynch, Vincent m.
AU - Yang, Jian
AU - Sedgwick, Adam c.
AU - Tondreau, Aaron
AU - Sessler, Jonathan l.
N1 - Funding Information:
The work at UT Austin was supported through the Robert A. Welch Foundation (F-0018). D.N.M. and G.J.J. would also like to thank the Seaborg Fellowship program of the Glenn T. Seaborg Institute for supporting research tenures at the Los Alamos National Laboratory (manuscript LA-UR-22-32546); S.H.C. also received postdoctoral support (in part) from the Glenn T. Seaborg Institute. A.M.T. and S.H.C. would like to thank Los Alamos National Laboratory, which is operated by Triad National Security, LLC, for the National Nuclear Security Administration of the U.S. Department of Energy (Contract No. 89233218CNA000001). A.M.T. and S.H.C. acknowledge the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, Heavy Element Chemistry Program (2020LANLE372). We thank Kyung Tae Kim of the Department of Civil, Architecture, and Environmental Engineering, The University of Texas at Austin for helping in carrying out the ICP-OES measurements.
Publisher Copyright:
© 2023 American Chemical Society.
PY - 2023/10/11
Y1 - 2023/10/11
N2 - Deferasirox is an FDA-approved iron chelator used in the treatment of iron toxicity. In this work, we report the use of several deferasirox derivatives as lanthanide chelators. Solid-state structural studies of three representative trivalent lanthanide cations, La(III), Eu(III), and Lu(III), revealed the formation of 2:2 complexes in the solid state. A 1:1 stoichiometry dominates in DMSO solution, with Ka values of 472 ± 14, 477 ± 11, and 496 ± 15 M-1 being obtained in the case of these three cations, respectively. Under the conditions of competitive precipitation in the presence of triethylamine, high selectivity (up to 80%) for lutetium(III) was observed in competition with La(III), Ce(III), and Eu(III). Theoretical calculations provided support for the observed selective crystallization.
AB - Deferasirox is an FDA-approved iron chelator used in the treatment of iron toxicity. In this work, we report the use of several deferasirox derivatives as lanthanide chelators. Solid-state structural studies of three representative trivalent lanthanide cations, La(III), Eu(III), and Lu(III), revealed the formation of 2:2 complexes in the solid state. A 1:1 stoichiometry dominates in DMSO solution, with Ka values of 472 ± 14, 477 ± 11, and 496 ± 15 M-1 being obtained in the case of these three cations, respectively. Under the conditions of competitive precipitation in the presence of triethylamine, high selectivity (up to 80%) for lutetium(III) was observed in competition with La(III), Ce(III), and Eu(III). Theoretical calculations provided support for the observed selective crystallization.
UR - http://www.scopus.com/inward/record.url?scp=85173584833&partnerID=8YFLogxK
U2 - 10.1021/jacs.3c08375
DO - 10.1021/jacs.3c08375
M3 - Article
SN - 0002-7863
VL - 145
SP - 22206
EP - 22212
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
IS - 40
ER -